ATLANTA, Aug. 5, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.
Artivion's management team will present at the upcoming Canaccord Genuity 44th Annual Growth Conference on Wednesday, August 14, 2024 at the InterContinental Boston Hotel. The Company's presentation is scheduled to begin at 2:00p.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
Artivion management will also be participating in investor meetings at the 9th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Monday and Tuesday, August 12-13, 2024. Due to the format of this event no webcast will be available.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.
Contacts:
Artivion Lance A. Berry Executive Vice President & | Gilmartin Group LLC Brian Johnston / Laine Morgan This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$28.48 |
| Daily Change: | 0.51 1.82 |
| Daily Volume: | 679,877 |
| Market Cap: | US$1.190B |
November 07, 2024 October 10, 2024 August 08, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
